Mankind Pharma Ltd

Mankind Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Mankind Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Mankind Pharma Ltd has witnessed a notable 16.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight price dip of 0.41% on 24 Apr 2026, the pharmaceutical mid-cap’s derivatives market shows increased volume and participation, reflecting complex directional bets amid broader sector and market trends.

Mankind Pharma Ltd has witnessed a notable 14.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest price decline of 0.64% on 24 Apr 2026, the pharmaceutical mid-cap’s derivatives market reveals complex directional bets amid broader sector and index weakness.

Mankind Pharma Ltd has witnessed a notable 13.1% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight price dip of 0.25% on 24 Apr 2026, the pharmaceutical mid-cap continues to attract significant volume and delivery participation, reflecting complex directional bets amid broader sector and market weakness.

Mankind Pharma Ltd has witnessed a notable 13.44% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the surge in open interest alongside rising volumes suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock has outperformed its sector peers, registering a 2.39% gain on 23 Apr 2026, supported by a 27.23% increase in open interest, reflecting growing bullish sentiment despite a recent downgrade in its Mojo Grade to Sell.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This increase accompanies a robust price rally, with the stock outperforming its sector and maintaining a steady upward trajectory over the past week.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock has outperformed its sector peers, gaining nearly 3% in a single day, while open interest jumped by almost 25%, reflecting increased speculative interest and potential directional bets.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock has outperformed its sector peers, registering a 3.41% gain on 23 Apr 2026, supported by a 21.5% increase in open interest and sustained volume growth, reflecting renewed bullish sentiment despite a recent downgrade in its Mojo Grade to Sell.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers, gaining 2.37% on the day, supported by a 20.9% increase in open interest and sustained volume growth, reflecting renewed bullish sentiment despite a recent downgrade in its Mojo Grade.

Mankind Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 14 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Mankind Pharma Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish stance, reflecting a complex interplay of technical indicators. Despite a modest daily price gain of 1.03%, the stock remains under pressure from longer-term bearish signals, prompting a downgrade in its Mojo Grade from Hold to Sell as of 19 Nov 2025.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by deteriorating technical parameters, reflects growing investor caution amid price weakness and subdued market sentiment.

Mankind Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling heightened investor participation and potential shifts in market positioning. The stock outperformed its sector and broader indices, supported by increased volumes and a sustained upward price trend over recent sessions.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector and broader indices, supported by rising volumes and a notable increase in delivery volumes, suggesting growing investor conviction despite a recent downgrade in its mojo rating.